Hoth Therapeutics, Inc. — Form D
Hoth Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2023-01-04. The offering totals $10.0M, of which $10.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-01-04
- Form: D
- Accession: 0001213900-23-000912
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.0M
- Amount sold: $10.0M
- Investors: 1
- Date of first sale: 2023-01-03
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-469705
Issuer
- Name: Hoth Therapeutics, Inc.
- CIK: 0001711786
- Entity type: Corporation
- Jurisdiction: NEVADA
- Incorporated: 2017
- Address: 1 ROCKEFELLER PLAZA, NEW YORK, NY, 10020
- Phone: (646) 756-2997
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Robb Knie | Director | RED BANK, NJ |
| Wayne Linsley | Director | SARASOTA, FL |
| Jeff Pavell | Director | SARASOTA, FL |
| David Sarnoff | Director | New York, NY |
| Graig Springer | Director | New York, NY |
| David Briones | Executive Officer | New York, NY |
| Robb Knie | Executive Officer | RED BANK, NJ |
| Vadim Mats | Director | Roseland, NJ |
| Robb Knie | Promoter | RED BANK, NJ |
| Kenneth Rice | Director | Dartmouth, A5 |
| Stefanie Johns | Executive Officer | New York, NY |
| Anthony Hayes | Director | Waltham, MA |
| David B Sarnoff | Director | New York, NY |
Other filings by this issuer (5)
More